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A B S T R A C T
Thirty HIV-seronegative cancer patients with
active tuberculosis were evaluated. Eighteen
(60%) were immigrants, 19 (63%) had haemato-
logical malignancy, and fever was the most
common presentation (97%). Of 19 (63%) patients
with pulmonary tuberculosis, 11 (58%) were
misdiagnosed initially as suffering from cancer
following radiography. Death was attributed to
tuberculosis for six (21%) of 29 patients who
received anti-mycobacterial therapy. All four
patients who had received high-dose systemic
corticosteroids within 4 weeks of diagnosis of
infection died, whereas two (8%) deaths occurred
in 25 individuals without corticosteroid exposure
(p < 0.001; OR 8.67). At this institution, active
tuberculosis was rare, and was seen mostly in
immigrants. Recent high-dose corticosteroid ther-
apy is a significant predictor of mortality in cancer
patients with tuberculosis.
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Mycobacterium tuberculosis is a serious infection
worldwide; 8 million new cases and 3 million
deaths ⁄ year have a substantial impact on global
public health [1]. Compared with the general
population, patients with adaptive cellular
immune dysfunction are at increased risk of active
tuberculosis [2]. Among oncology patients, those
withHodgkin’s diseases and head and neck cancer
have been considered to be at high risk of infection
[3]. Patients undergoing allogeneic haematopoietic
stem cell or organ transplantation in regions
endemic for M. tuberculosis are also at increased
risk [4]. However, the risk for transplant recipients
in the USA and Europe remains low, although
M. tuberculosis in immigrant populations in the
USA remains an important health care concern
[5,6].
During the last decade, urban outbreaks of
isoniazid- and rifampicin-resistant M. tuberculosis
strains have caused grave public health concern
[7]. In contrast to patients infected with HIV,
multidrug-resistant (MDR) tuberculosis is seldom
observed in patients with cancer or following stem
cell transplantation. The purpose of this study was
to determine the characteristics of active tubercu-
losis in cancer patients during the 1990s.
All patients seen between 1 January 1990 and
30 June 2000 at the MD Anderson Cancer Center
(Houston, TX, USA) with positive M. tuberculosis
cultures were reviewed retrospectively. Patient
and laboratory data were retrieved from the
patients’ charts and the hospital computer sys-
tems. Patients diagnosed with HIV, and a case
reported previously [8], were excluded from the
study. M. tuberculosis was isolated and identified
by standard methods [9]. Antimicrobial suscepti-
bility was determined according to National
Committee for Clinical Laboratory Standards
guidelines [10]. Disseminated tuberculosis was
defined as infection involving two or more
non-contiguous body sites, while neutropenia
(granulocytopenia) was < 500 cells ⁄mm3, and
lymphocytopenia was < 500 cells ⁄mm3. Signifi-
cant corticosteroid use was defined as a cumula-
tive dose of ‡ 15 mg ⁄day of prednisone
equivalent within the 4 weeks before diagnosis
of infection. Protein–energy malnutrition was
severe if the body mass index was < 16.0 kg ⁄m2.
Death was attributed to M. tuberculosis in the
absence of other terminal precipitating causes and
with histological evidence of tuberculosis.
Thirty of 48 patients with active tuberculosis
were included in the study. These 30 patients had a
median age of 54 years (range, 23–88 years). Dur-
ing the 10 years of the study, the overall frequency
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of active tuberculosis was 0.2 ⁄ 1000 new cancer
diagnoses, and 1.3 ⁄ 1000 new leukaemia diagno-
ses. Patient characteristics are listed in Table 1. Of
the 18 patients born in countries outside the USA,
11 (61%) were from Latin America.
Table 2 shows the disease characteristics in the
30 patients. Five of 19 patients with lung disease
had concurrent pleural effusion, and tuberculous
pleurisy was present in three (10%) patients. Acid-
fast bacilli were identified in 35% of bronchoal-
veolar lavage samples on cytological examination,
whereas all except one bronchoalveolar lavage
culture sample (95%) in patients with pulmonary
tuberculosis were diagnostic. Four patients had
received haematopoeitic stem cell transplants;
three of these had isolated pulmonary disease,
and one presented with tuberculous lympha-
denitis. The interval from transplant to diagnosis
of tuberculosis ranged from 2 to 379 days.
Twenty-nine (97%) patients had received
appropriate antimicrobial therapy. Seven (23%)
patients died; anti-tuberculosis therapy was not
commenced in one of these patients, and the
correct diagnosis was delayed in five patients.
Despite appropriate antimicrobial therapy, all four
patients who received high-dose corticosteroids
died, compared to only two deaths in 25 patients
with no history of corticosteroid use (p < 0.001;
OR 8.67). All 28 isolates of M. tuberculosis were
susceptible to first-line anti-tuberculosis agents.
Active tuberculosis was uncommon in the can-
cer patients studied, and was seen mostly in
patients born in countries outside the USA. In
these individuals, in contrast to persons born in the
USA, tuberculosis probably represented reactiva-
tion of latent infection [11, 12]. It was interesting to
note that most patients did not receive systemic
corticosteroids, and that severe protein–calorie
malnutrition was conspicuously absent in this
group. The high mortality rate (100%) observed in
patients receiving high-dose systemic corticoster-
oids, compared with those who did not, suggests
prompt discontinuation of corticosteroids in can-
cer patients with active tuberculosis. However, the
low rate of infection-related deaths (< 10%) in
cancer patients without recent significant corticos-
teroid exposure was encouraging.
A high proportion of patients had a haemato-
logical malignancy, especially leukaemia, with
active tuberculosis. This was in contrast to previ-
ous reports indicating a higher rate of tuberculosis
in patients with solid-organ malignancy and
Hodgkin’s disease [3]. Active tuberculosis was an
uncommon opportunistic complication in the stem
cell transplant recipients, and all four patients in
this group presented with localised, non-dissem-
inated disease that responded to therapy.
Table 1. Characteristics of 30 patients with cancer and
Mycobacterium tuberculosis infection
Patient characteristics Number (%) of patients
Male:female 19:11
Immigrant 18 (60)
Neutropenia (cells ⁄mm3; absolute neutrophil count < 500) 6 (20)
Lymphocytopenia (< 500 cells ⁄mm3) 6 (20)
Systemic corticosteroids 4 (13)
Protein–energy malnutrition 6 (20)
Mild to moderate (BMI 18.4–16 kg ⁄m2) 3
Severe (BMI < 16.0 kg ⁄m2) 3
Underlying cancer 30 (100)
Haematological malignancy 19 (63)
Leukaemiaa 10
Lymphomab 6
Myelodysplastic syndrome 2
Multiple myeloma 1
Haematopoietic stem cell transplantation 4 (13)
Solid-organ malignancy 11 (37)
Head and neck cancer 4
Breast carcinoma 2
Urinary bladder cancer 2
Othersc 3
BMI, body mass index.
aLeukaemia included chronic myelogenous leukaemia (n = 4), acute myelogenous
leukaemia (n = 4), and acute (n = 1) and chronic (n = 1) lymphocytic leukaemia.
bOf six patients with lymphoma, five had non-Hodgkin’s lymphoma and one had
Hodgkin’s disease.
cOthers include one patient each with rectal cancer, cervical carcinoma and
fibrosarcoma.
Table 2. Characteristics of Mycobacterium tuberculosis
infection in 30 patients with cancer
Infection characteristics Number (%) of patients
Clinical presentation
Fever 29 (97)
Anorexia 20 (67)
Cough 19 (63)
Dyspnoea 18 (60)
Weight loss 10 (33)
Haemoptysis 9 (30)
Night sweats 8 (27)
Site of infection
Pulmonarya 19 (63)
Unilateral upper-lobe disease 14
Bilateral upper-lobe disease 2
Diffuse-nodular upper-lobe disease 1
Middle-lobe cavitary disease 1
Miliary disease pattern 1
Lymphadenitis 4 (13)
Pleurisy 3 (10)
Meningitis 1 (3)
Psoas abscess 1 (3)
Chest wall abscess 1 (3)
Disseminated miliary disease 1 (3)
Disease outcome
Death attributed to M. tuberculosisb 7 (23)
Received anti-mycobacterial combination therapy 29 (97)
Responded to therapyc 23 (79)
Deaths attributed to M. tuberculosis in treated group 6 (21)
aFive patients with upper-lobe disease had concomitant pleural effusion.
bDeaths were attributed to M. tuberculosis if there was autopsy-proven tuberculous
organ disease or severe damage to organs.
cAnti-mycobacterial agents were not given to one patient whose death was
attributed to M. tuberculosis.
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The emergence and global spread of MDR
M. tuberculosis is a serious concern, as these
infections are refractory to conventional therapy
[7], and successful treatment often involves a
multi-faceted approach [8, 13]. In the present
report, all clinical isolates of M. tuberculosis from
cancer patients were susceptible to first-line anti-
microbial agents. Ineffective person-to-person
transmission of MDR M. tuberculosis [14] may be
responsible, in part, for the absence of drug-
resistant infection in the cancer patients studied.
Alternatively, most active tuberculosis in immi-
grants probably involved reactivation of a drug-
susceptible mycobacterial infection acquired
remotely. The paucity of MDR mycobacteriosis
may have played an important role in promoting a
favourable treatment outcome in the patients
without corticosteroid exposure [14,15].
Tuberculosis can imitate the clinical and
radiographic features of various diseases; abdom-
ino-pelvic infections may occasionally be misin-
terpreted as cancer [16,17]. In this report, nearly
60% of patients with focal pulmonary tuberculo-
sis were thought initially to have cancer. Import-
antly, tuberculosis can coexist with cancer [18,19],
and a high level of suspicion is crucial in this
select group of patients. In accordance with the
results of this study, others have reported higher
bronchoscopic diagnostic yields compared to
sputum cultures [20]. For patients with a high
pre-test probability of coexisting tuberculosis and
cancer, trans-thoracic fine needle aspiration or
evaluation of surgically obtained lung tissue may
facilitate a timely diagnosis [21].
In conclusion, tuberculosis was rare in the
cancer patients and stem cell transplant recipients
studied. Infection was most prominent in immi-
grants, and leukaemia was observed to be an
important underlying malignancy. The paucity of
conventional predictors of tuberculosis, such as
lymphocytopenia, severe malnutrition and sys-
temic corticosteroids, was unexpected. A favour-
able treatment response can be expected in cancer
patients with active tuberculosis who have not
recently undergone high-dose systemic cortico-
steroid therapy.
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A B S T R A C T
During a survey of extended-spectrum b-lacta-
mase (ESBL)-producing Enterobacteriaceae in
Bulgaria in 2001–2002, three isolates from Sofia
(two Escherichia coli, one Klebsiella pneumoniae)
showed cefotaxime MICs that were decreased in
the presence of clavulanate and were 2–8-fold
higher than those of ceftazidime. Resistance was
transferred to a sensitive recipient strain of E. coli.
Both wild-type and transconjugant strains pro-
duced a cefotaxime-hydrolysing b-lactamase of pI
8.8. Sequencing of the PCR product obtained with
oligonucleotide primers binding outside the
coding region identified this b-lactamase as
CTX-M-15. To our knowledge, this is the first
report of CTX-M-15 in Bulgaria.
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CTX-M-type b-lactamases are a group of class A
extended-spectrum b-lactamases (ESBLs) that are
growing rapidly in importance [1,2]. CTX-M-1,
the first CTX-M-type b-lactamase, was detected in
an isolate of Escherichia coli from Germany in 1989
[2], and the overall number of cefotaximases has
now increased to c. 40 [3]. Most CTX-M-type
b-lactamases are 4–16-fold more active against
cefotaxime than against ceftazidime [1,4], but
enzymes with enhanced activity against ceftazi-
dime have been detected recently, namely CTX-
M-15, -16, -19 and -27 [4–8]. CTX-M-15 was first
described in India in 2001 [5], and was then
identified subsequently in Poland, France, Tur-
key, Romania and the UK [4,9–12].
During a prospective survey of ESBLs in
Enterobacteriaceae from seven Bulgarian univer-
sity hospitals in 2001–2002, 62 ESBL-producing
isolates were detected. Of these, three strains from
Sofia were identified (see below) as CTX-M-15
producers: E. coli Sof10 was isolated on 9 February
2001 from the urine of a female ambulatory
patient aged 60 years; Klebsiella pneumoniae Sof9
was isolated on 18 April 2002 from the blood
culture of a male patient, aged 47 years, in an
intensive care unit; and E. coli Sof11 was recovered
on 21 February 2002 from the blood culture of a
boy, aged 10 months, with pyelonephritis.
Antimicrobial susceptibilities were determined
by disk diffusion and an agar dilution procedure,
performed according to National Committee for
Clinical Laboratory Standards guidelines [13].
Plasmid transfer was performed on Mueller–
Hinton agar by mixing 0.8-mL portions of
18–24-h Luria–Bertani broth cultures of the donor
and recipient (E. coli K12:W3110 Rif
r lac–) strains.
Transconjugants were selected on MacConkey
agar containing cefotaxime 2 mg ⁄L and rifampi-
cin 50 mg ⁄L. Analytical isoelectric focusing was
done according to the method of Mathew et al.
[14] with modifications [2]. A bioassay was used
to determine the hydrolytic activity of the distinct
b-lactamase bands after isoelectric focusing as
Corresponding author and reprint requests: R. Markovska,
Department of Microbiology, Medical University, 2 Zdrave
Str., 1431 Sofia, Bulgaria
E-mail: markovska73@abv.bg
752 Clinical Microbiology and Infection, Volume 10 Number 8, August 2004
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 749–772
